

Alternative Defibrillation Strategies for Refractory Ventricular Fibrillation: A Systematic Review and Meta-Analysis

Benedetta Perna^{1*} (prnbdt@unife.it), Matteo Guarino^{1,2*} (grnmtt@unife.it), Roberto de Fazio¹ (dfzrrt@unife.it), Ludovica Esposito¹ (ludovica.esposito@unife.it), Andrea Portoraro¹ (prtndr1@unife.it), Federica Rossin^{2,3} (rssfrc1@unife.it), Francesca Remelli⁴ (rmlfnc1@unife.it), Caterina Trevisan⁴ (caterina.trevisan@unife.it), Valeria Raparelli¹ (valeria.raparelli@unife.it), Giovanni Marasco^{5,6} (giovanni.marasco4@unibo.it), Giovanni Barbara^{5,6} (giovanni.barbara@unibo.it), Stefano Petrini² (petrinist@libero.it), Milo Vason² (m.vason@ospfe.it), Michele Domenico Spampinato^{1,2} (sppmhl@unife.it), Roberto De Giorgio¹ (dgrrrt@unife.it)

¹Department of Translational Medicine, St. Anna University Hospital of Ferrara, University of Ferrara, Italy

²Emergency Department, S. Anna University Hospital of Ferrara, Italy

³Emergency Medicine, Azienda Unità Sanitaria Locale, Ferrara, Italy

⁴Department of Medical Sciences, St. Anna University Hospital of Ferrara, University of Ferrara, Italy

⁵IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.

⁶Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

*These two authors share co-first authorship

Word count: 2254

Correspondence to:

Michele Domenico Spampinato

Department of Translational Medicine

St. Anna University Hospital - Via A. Moro, 8

44124 – Ferrara, Italy

Tel.: +39 3803684962

E-mail: sppmhl@unife.it

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Acknowledgments

The authors wish to thank Dr. Donato Bragatto, Dr. Claudia Righini, Mrs. Manuela Zappaterra (Biblioteca Interaziendale di Scienza della Salute, Hospital of Ferrara), Mrs. Egizia Zironi and Mrs. Silvia Bellotti (Unità Servizi Interbibliotecari, University of Ferrara) for their valuable collaboration. Furthermore, the authors thank Alice Eleonora Cesaro and Greta Francesca Cesaro for image editing.

Abstract

Background: Cardiac arrest with refractory ventricular fibrillation (rVF) represents a dramatic medical emergency. Despite recent advances, its treatment is challenging and burdened by limited evidence. This systematic review and meta-analysis aims at establishing whether alternative defibrillation strategies (ADS), i.e. double sequential external defibrillation (DSED) or vector-change defibrillation (VCD), improve survival among patients with rVF compared to standard defibrillation (SD).

Methods: Randomized clinical trials (RCTs), prospective and retrospective studies were included if: (1) compared ADS with SD in rVF; (2) conducted on patients ≥ 18 years old; (3) reported survival to hospital admission. English-language papers from MEDLINE, Google Scholar, Cochrane Library, World Health Organization, EMBASE and CINAHL, published from inception to December 2022, were retrieved. The risk of bias was assessed following the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies and the revised Cochrane risk of bias tool for randomized trials, as appropriate. A random-effects meta-analysis was performed to estimate the pooled Odds Ratio (pOR) with 95% Confidence Interval (95%CI) of ADS and survival to hospital admission. Furthermore, a subgroup analysis was performed to compare SD with each type of ADS. The protocol was registered on PROSPERO (CRD42022379049).

Results: Eight studies (2 RCTs, 5 retrospective and 1 case-control study) were retrieved for qualitative and quantitative analyses. The study population included 1405 patients (ADS = 493 vs. SD = 912) with a pooled mean age of 61.9 ± 1.1 years; among them, 277 (19.7%) were female. The random-effect meta-analysis did not show differences in survival to hospital admission among ADS vs. SD (pOR = 1.12, 95%CI: 0.62-2.01). The subgroup analysis confirmed that neither DSED (pOR = 1.20, 95%CI: 0.56-2.58) nor VCD (pOR = 1.66, 95%CI: 0.10-27.02) were associated with improved survival to hospital admission. Main limitations were: i) few numbers of studies included with small sample size; and ii) female under-representation.

Conclusion: The present manuscript did not show any difference on survival to hospital admission between the considered defibrillation strategies in rVF. This result highlights the need for further *ad hoc* clinical trials assessing the actual role of ADS.

Keywords: Alternative defibrillation strategies; cardiac arrest; double sequential external defibrillation; refractory ventricular fibrillation; resuscitation; vector-change defibrillation.

Statements and Declaration

Competing interests: Authors have no conflicts of interest to disclose.

Funding: RDG was supported by FAR (Fondo Ateneo Ricerca) and FIR (Fondo Incentivazione Ricerca) funds from the University of Ferrara, Italy.

Reproducible Research Statement: The study protocol was registered on PROSPERO (CRD42022379049).

Statistical code and data set: All data and statistical analyses codes are available upon request to the corresponding author.

Ethical Approval: This research does not directly involve patients; hence, an ethical approval was deemed unnecessary.

Authors' contributions: BP and MG designed the project and wrote the paper. BP, MG, RdF, LE, AP and FR built the database. FRe and CT analysed the database. BP, MG, VR, GM, GB, VS, SP, MV, MDS and RDG critically reviewed the paper. All authors have read and agreed to the published version of the manuscript.

Availability of data and materials: The dataset is available for reviewers on reasonable request.

Background

Cardiac arrest (CA) is a condition characterized by the interruption of cardiac mechanical activity in the absence of any circulation sign [1]. In 2021, out-of-hospital cardiac arrest (OHCA) has been identified by United States Emergency Medical Service (EMS) in around 150000 individuals [2], but the real incidence is unknown because most cases are not managed by EMS [3]. In-hospital cardiac arrest (IHCA) is also common, occurring almost 290000 patients in the United States every year [4]. Both conditions are burdened by poor survival rates (9.1% and 18.8% for OHCA and IHCA, respectively) and among survivors, only 7.1% and 12.9%, respectively, had good functional status [2]. Sex disparities in the epidemiology of CA have been reported. Specifically, OHCA is more common in males than females (69% vs. 31%). Concordantly, IHCA occurs more frequently in males (58%) with a mean age of 66 years [4,5]. CA may have two different clinical presentations: one with shockable rhythm, i.e. ventricular fibrillation (VF) or pulseless ventricular tachycardia (pVT); the other with non-shockable rhythm, i.e. asystolia or pulseless electric activity (PEA) [6]. Patients presenting with shockable rhythms have a higher survival rate than those with non-shockable ones [7]. Nevertheless, almost half of subjects with shockable rhythms may remain in refractory ventricular fibrillation (rVF), defined as VF or pVT still detectable after 3 consecutive rhythm analyses and standard defibrillations separated by 2-minute intervals [8]. In this population, neither further defibrillation or antiarrhythmic drugs, such as amiodarone and lidocaine, have been shown to improve survival to hospital discharge or neurologically preserved survival [9]. Alternative defibrillation strategies (ADS), i.e. double sequential external defibrillation (DSED) and vector-change defibrillation (VCD), have been suggested for rVF despite the body of evidence is still scanty [10-11]. DSED is the simultaneous use of two sets of manual defibrillators in two different planes (anterior-lateral and anterior-posterior) to double the defibrillation energy [12], while VCD consists in shifting defibrillation pads from the usual anterior-lateral position to the anterior-posterior one [13] (Figure 1). The association between ADS and rVF survival has been

studied with discordant findings mainly due to methodological drawbacks of the conducted studies [8,14-22]. Indeed, only two studies reported a significant difference between ADS and standard defibrillation (SD), suggesting a superiority of the former on survival [8,22]. Since survival to hospital discharge might be burdened by several confounding factors related to hospitalization, the present systematic review and meta-analysis aimed to investigate whether ADS improve survival to hospital admission vs. SD in adults with non-traumatic rVF.

Methods

This paper has been performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [23] and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and checklists [24]. The protocol was registered on PROSPERO (CRD42022379049).

Data sources and searches

English-language studies on human subjects from MEDLINE, Google Scholar, World Health Organization (WHO), LitCovid NLM, EMBASE, CINAHL Plus and Cochrane Library were retrieved from January 2000 to December 2022. A combination of subject headings and keywords relevant to ADS and rVF were combined using Boolean terms, as appropriate. The complete search strategy included: “refractory ventricular fibrillation” OR “cardiac arrest” OR “ventricular fibrillation” OR “VF” OR “pulseless ventricular tachycardia” OR “pVT” AND “double-sequential external defibrillation” OR “dual-sequential external defibrillation” OR “DSED” OR “vector-change defibrillation” OR “VCD” OR “defibrillation strategies” (see Supplementary Table 1). Furthermore, relevant papers were hand-retrieved to identify further studies that might have been missed by the electronic analysis (BP and MG).

Study selection

Randomized controlled trials (RCTs), prospective and retrospective studies (including cross-sectional studies and case series with at least five patients) were searched. Studies were eligible if: (1) they compared the use of an ADS *vs.* SD in patients with rVF; (2) patients enrolled were older than 18 years; (3) data on survival to hospital admission were available. Four Authors (RdF, LE, AP and FR), working in pairs, independently screened citation titles and abstracts and retrieved full manuscripts and appendices of potentially relevant articles. Disagreements and inconsistencies were resolved by adjudication with three investigators (BP, MDS, MG).

The meta-analysis was performed comparing studies which expressed the number of patients survived to hospital admission and the sample size of the following subgroups: experimental group (i.e. ADS) *vs.* control group (SD).

Data extraction and quality assessment

Two reviewers (BP and MG) independently abstracted and recorded data, using standardized data abstraction form (Excel spreadsheet). The investigators were blinded to each other decisions. Disagreements were resolved by consensus and arbitration with a third reviewer (MDS). The following data were extracted: author's name; year of publication; duration of the analysis; study design; sample size; mean age; female sex; ADS technique; numerosity of experimental and control groups; p-value of ADS *vs.* SD on survival to hospital admission in the univariate analysis; percentage of patients in the experimental group survived to hospital admission; main conclusion. Investigators performed a single contact attempt with study Authors if any data were not available. The quality assessment of the included studies has been performed following the National Institutes of Health (NIH) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [25] and the revised Cochrane risk of bias tool for randomized trials (Risk of Bias-2, RoB-2), as appropriate [26]. Two independent investigators scored each article for quality and scoring

inconsistencies were resolved by discussion and consensus between the two reviewers (BP and MG).

Data synthesis and analysis

A random-effects meta-analysis was performed using the *meta* package of R statistical software (version 4.2.2) to estimate the pooled Odds Ratio (OR) with 95% Confidence Interval (95% CI) of the different defibrillation strategies and survival to hospital admission [27]. I^2 statistic was used to evaluate the heterogeneity across the studies: a considerable heterogeneity was established with an I^2 statistic $>75\%$ and the statistical significance was set at $p < 0.05$. All the mentioned analyses were repeated solely on the observational studies, after excluding RCTs.

The publication bias of the involved studies was evaluated both graphically and numerically through Funnel plots and Egger's regression test, respectively. Two subgroup analyses were performed to compare SD with the single alternative procedures (i.e. DSED or VCD).

Results

Literature Search Results

A total of 3360 papers were retrieved through database searching (Figure 2). Hand searching of literature did not identify any further eligible articles. After removing duplicate records, studies conducted on animals and non-English manuscript, 552 papers were identified for screening. Subsequently, 281 citations were excluded, leaving 271 manuscripts for full review. After exclusion of irretrievable papers / studies with unclear or different primary outcome, 8 documents were included in the analysis (Figure 2).

Study characteristics

We retrieved 2 RCTs, 5 retrospective observational and 1 case-control studies. Excluding 152 patients enrolled in both the RCTs by Cheskes *et al.* [8,21], a total of 1405 patients were analysed with a pooled mean age of 61.9 ± 1.1 years. Among participants, 277 (19.7%) were female. Five papers analysed the effect of DSED on survival to hospital admission [16,17,19,20,22], one evaluated VCD vs. SD [18] and two RCTs compared ADS to SD in rVF [8,21]. Pooled survival rate in experimental group was $32.3 \pm 12.7\%$. The main features of the selected papers were summarized in Table 1.

Quality assessment and publication bias

Using the NIH quality assessment tool, we evaluated 6 out of 8 studies, as appropriate. Three out of six papers had a poor-quality rating [16-18] and three a fair-quality one [19,20,22]. RoB-2 assessment highlighted an overall low risk of bias of the two RCTs involved [8,21]. No studies were excluded because of a poor-quality rating (<50%). Quality assessments are reported in Supplementary Table 2 and 3. The heterogeneity among all the selected studies was moderate ($I^2 = 62\%$, $p = 0.01$) and no publication bias resulted from qualitative (Supplementary Figure 1) and quantitative (Egger regression intercept = 1.029, 95%CI: -2.728, 4.785, $p = 0.608$) analyses. Among the observational studies, the heterogeneity was low ($I^2 = 27\%$, $p = 0.23$) and both the funnel plot and the Egger's test (Egger regression intercept = 2.223, 95%CI: 0.241, 4.209, $p = 0.089$) suggested the presence of possible publication bias.

Defibrillation strategies and survival to hospital admission

The random-effect meta-analysis demonstrated no significant differences in survival to hospital admission among ADS vs. SD ($n = 1405$, pooled OR = 1.12, 95%CI: 0.62, 2.01; Figure 3). This result was confirmed after the exclusion of the patients enrolled in both the RCTs [8,21] ($n = 1000$, pooled OR=0.86, 95%CI: 0.51, 1.47; Figure 4).

The subgroup analyses confirmed that neither DSED (n=1,236, pooled OR=1.20, 95%CI: 0.56, 2.58; Supplementary Figure 2a) nor VCD (n=305, pooled OR=1.66, 95%CI: 0.10, 27.02; Supplementary Figure 2b) were associated with survival benefit to hospital admission *vs.* SD.

Discussion

This systematic review and meta-analysis demonstrated that the defibrillation strategy does not influence the rate of survival to hospital admission in adults with rVF.

CA is the most dramatic condition among medical emergencies [6]. Although shockable rhythms have usually better outcomes than non-shockable ones, their progression to rVF is burdened by high mortality rates. The treatment of this condition is still challenging and a specific, well-defined management has not been proposed yet [28]. Even the latest 2021 guidelines by the European Resuscitation Council (ERC) did not conclude for a specific treatment of rVF. Indeed, the Authors suggested to consider the use of VCD, while a weak recommendation against DSED was provided based on low-certainty evidence [29]. Considering these uncertainties and the conflicting data from the RCT recently published [8], the present manuscript aimed at investigating the effects of both DSED and VCD *vs.* SD on survival to hospital admission in patients with rVF.

Most studies included in the systematic review proposed a role of ADS in the management of rVF [8,18,21,22]. Only two studies highlighted a significant difference on survival to hospital admission of ADS *vs.* SD [8,22]. In 2022, Cheskes *et al.* performed a RCT involving a large sample size and showing a low risk of bias at the quality assessment [8]. In contrast, Kim *et al.* carried out a retrospective analysis limited by low numerosity and a questionable quality assessment with an uncommonly high survival rate [22].

Regarding the effect of VCD in rVF, Stupca *et al.* retrospectively assessed 83 patients reporting a negative effect of this technique on return of spontaneous circulation (ROSC) and survival to hospital admission / discharge [30]. However, VCD-treated patients also received active

pharmacological therapies (i.e., esmolol and dose-capped epinephrine), thus leading to the exclusion of this study from our analysis.

The main message emerged from our analysis was the lack of difference on survival to hospital admission between ADS and SD. This finding is in line with the conclusions of previous systematic review [31] and meta-analyses [32,33]. Nonetheless, our analysis comprehended the most recent RCT [8] and addressed a different primary outcome from the aforementioned studies. Indeed, our main goal was the evaluation of the survival to hospital admission instead of survival to hospital discharge, which may be biased by confounding factors related to hospitalization. The subgroup analyses confirmed that neither DSED nor VCD vs. SD improved survival to hospital admission in patients with rVF, corroborating the results obtained in the meta-analysis performed on ADS.

Despite the 2016 Sex And Gender Equity In Research guidelines encouraged to perform a sex- and gender-based analysis (SGBA), none of the included studies reported sex-disaggregated findings [34]. Moreover, although up to 42% of patients experiencing CA were females [4,5], the percentage of women enrolled in the included studies was only 19.0%. The female underrepresentation in clinical studies has been commonly reported, especially in cardiovascular clinical trials [35,36], limiting the generalizability of trial findings. Also in the present meta-analysis, we confirmed the lack of data on treatment outcomes in female adults with rVF. Recently, sex-based differences in CA management and survival have been reported. Female adults experiencing OHCA had a small absolute difference for the outcome survival to discharge as compared with the male counterpart, while no difference in survival at 30 days was detected [37]. A systematic review also reported how the unadjusted difference in the outcomes of male and female with CA may be explained by the worse phenotype of women such as the older age, greater burden of comorbidities and the higher proportion of less witnessed arrests with no shockable rhythms [38]. Therefore, more studies are needed to improve our understanding of CA in women.

The main strengths of the present analysis are that: i) it was the first systematic review and meta-analysis highlighting the effect of the different type of ADS on survival to hospital admission;

- ii) it was focused on a clinically meaningful outcome, influenced mostly by the applied treatment;
- iii) the heterogeneity of the included studies was moderate and no publication bias was detected.

Our findings should be carefully interpreted in the light of several limitations. First, inclusion criteria were met only by few studies and, among them, only two were RCTs. Second, the overall sample size exhibited a scarce numerosity with an unbalanced representation of female adults and no SGBA performed. Third, we considered only survival to hospital admission which, although clinically meaningful, did not describe the functional status of the discharged patients.

In conclusion, this systematic review and meta-analysis, which included the latest and largest RCT comparing the use of ADS *vs.* SD, did not show any difference on survival to hospital admission between the different defibrillation techniques in rVF. We acknowledge the statistical strength of a well-conducted RCT demonstrating the survival benefit of ADS *vs.* SD. Nevertheless, considering the contrasting results emerged from this meta-analysis, our study advocates for further well-designed clinical trials, including SGBA, aimed at establishing the actual role of ADS.

Abbreviations

ADS: alternative defibrillation strategies; CA: cardiac arrest; DSED: double sequential external defibrillation; EMS: emergency medical service; ERC: European Resuscitation Council; IHCA: in-hospital cardiac arrest; MOOSE: meta-analysis of observational studies in epidemiology; OHCA: out-of-hospital cardiac arrest; NIH: National Institutes of Health; PEA: pulseless electric activity; PRISMA: preferred reporting items for systematic reviews and meta-analyses; pVT: pulseless ventricular tachycardia; RCT: randomized controlled trial; RoB-2: Risk of Bias-2; ROSC: return of spontaneous circulation; rVF: refractory ventricular fibrillation; SD: standard defibrillation; SGBA: sex- and gender-based analysis; VCD: vector-change defibrillation; VF: ventricular fibrillation.

References

1. Jacobs I, Nadkarni V, and the ILCOR Task Force on Cardiac Arrest and Cardiopulmonary Resuscitation Outcomes. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Councils of Southern Africa). *Circulation*. 2004; 110:3385-3397. doi: 10.1161/01.CIR.0000147236.85306.15.
2. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*. 2023; 147:e93-e621. doi: 10.1161/CIR.0000000000001123.
3. Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: current concepts. *Lancet*. 2018; 391:970-979. doi: 10.1016/S0140-6736(18)30472-0.
4. Andersen LW, Holmberg MJ, Berg KM, Donnino MW, Granfeldt A. In-Hospital Cardiac Arrest: A Review. *JAMA*. 2019; 321:1200-1210. doi: 10.1001/jama.2019.1696.

5. Dicker B, Conaglen K, Howie G. Gender and survival from out-of-hospital cardiac arrest: a New Zealand registry study. *Emerg Med J*. 2018; 35:367-371. doi: 10.1136/emered-2017-207176.
6. Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O'Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM; Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2020; 142:S366-S468. doi: 10.1161/CIR.0000000000000916.
7. Olasveengen TM, Samdal M, Steen PA, Wik L, Sunde K. Progressing from initial non-shockable rhythms to a shockable rhythm is associated with improved outcome after out-of-hospital cardiac arrest. *Resuscitation*. 2009; 80:24-29. doi: 10.1016/j.resuscitation.2008.09.003.
8. Cheskes S, Verbeek PR, Drennan IR, McLeod SL, Turner L, Pinto R, Feldman M, Davis M, Vaillancourt C, Morrison LJ, Dorian P, Scales DC. Defibrillation Strategies for Refractory Ventricular Fibrillation. *N Engl J Med*. 2022; 387:1947-1956. doi: 10.1056/NEJMoa2207304.
9. Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, Leroux B, Vaillancourt C, Wittwer L, Callaway CW, Christenson J, Egan D, Ornato JP, Weisfeldt ML, Stiell IG, Idris AH, Aufderheide TP, Dunford JV, Colella MR, Vilke GM, Brienza AM, Desvigne-Nickens P, Gray PC, Gray R, Seals N, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. *N Engl J Med*. 2016; 374:1711-1722. doi: 10.1056/NEJMoa1514204.
10. Bell SM, Lam DH, Kearney K, Hira RS. Management of Refractory Ventricular Fibrillation (Prehospital and Emergency Department). *Cardiol Clin*. 2018; 36:395-408. doi: 10.1016/j.ccl.2018.03.007.

11. Scaturo N, Shomo E, Frank M. Current and investigational therapies for the treatment of refractory ventricular fibrillation. *Am J Health Syst Pharm.* 2022; 79:935-943. doi: 10.1093/ajhp/zxac011.
12. Miraglia D, Ramzy M. Double external defibrillation for shock-refractory ventricular fibrillation cardiac arrest: A step towards standardization. *Am J Emerg Med.* 2021; 41:73-79. doi: 10.1016/j.ajem.2020.12.031.
13. Stupca K, Scaturo N, Shomo E, King T, Frank M. Esmolol, vector change, and dose-capped epinephrine for prehospital ventricular fibrillation or pulseless ventricular tachycardia. *Am J Emerg Med.* 2023; 64:46-50. doi: 10.1016/j.ajem.2022.11.019.
14. Cabañas JG, Myers JB, Williams JG, De Maio VJ, Bachman MW. Double Sequential External Defibrillation in Out-of-Hospital Refractory Ventricular Fibrillation: A Report of Ten Cases. *Prehosp Emerg Care.* 2015; 19:126-130. doi: 10.3109/10903127.2014.942476.
15. Cortez E, Krebs W, Davis J, Keseg DP, Panchal AR. Use of double sequential external defibrillation for refractory ventricular fibrillation during out-of-hospital cardiac arrest. *Resuscitation.* 2016; 108:82-86. doi: 10.1016/j.resuscitation.2016.08.002.
16. Ross EM, Redman TT, Harper SA, Mapp JG, Wampler DA, Miramontes DA. Dual defibrillation in out-of-hospital cardiac arrest: A retrospective cohort analysis. *Resuscitation.* 2016; 106:14-7. doi: 10.1016/j.resuscitation.2016.06.011. doi: 10.1016/j.resuscitation.2016.06.011.
17. Emmerson AC, Whitbread M, Fothergill RT. Double sequential defibrillation therapy for out-of-hospital cardiac arrests: The London experience. *Resuscitation.* 2017; 117:97-101. doi: 10.1016/j.resuscitation.2017.06.011.
18. Davis M, Schappert A, Van Aarsen K, Loosley J, McLeod S, Cheskes S. P029: A descriptive analysis of defibrillation vector change for prehospital refractory ventricular fibrillation. *CJEM.* 2018; 20: S67-S67.

19. Beck LR, Ostermayer DG, Ponce JN, Srinivasan S, Wang HE. Effectiveness of Prehospital Dual Sequential Defibrillation for Refractory Ventricular Fibrillation and Ventricular Tachycardia Cardiac Arrest. *Prehosp Emerg Care*. 2019; 23:597-602. doi: 10.1080/10903127.2019.1584256.
20. Mapp JG, Hans AJ, Darrington AM, Ross EM, Ho CC, Miramontes DA, Harper SA, Wampler DA; Prehospital Research and Innovation in Military and Expeditionary Environments (PRIME) Research Group. Prehospital Double Sequential Defibrillation: A Matched Case-Control Study. *Acad Emerg Med*. 2019; 26:994-1001. doi: 10.1111/acem.13672.
21. Cheskes S, Dorian P, Feldman M, McLeod S, Scales DC, Pinto R, Turner L, Morrison LJ, Drennan IR, Verbeek PR. Double sequential external defibrillation for refractory ventricular fibrillation: The DOSE VF pilot randomized controlled trial. *Resuscitation*. 2020; 150:178-184. doi: 10.1016/j.resuscitation.2020.02.010.
22. Kim HE, Lee KJ, Jo YH, Lee JH, Kim YJ, Kim JH, Lee DK, Kim DW, Park SM, Oh YT. Refractory Ventricular Fibrillation Treated with Double Simultaneous Defibrillation: Pilot Study. *Emerg Med Int*. 2020; 2020:5470912. doi: 10.1155/2020/5470912.
23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021; 372:n71. doi: 10.1136/bmj.n71.
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology MOOSE group meta- analysis of observational studies in epidemiology: a proposal for reporting. *JAMA*. 2000; 283:2008-2012. doi: 10.1001/jama.283.15.2008.
25. National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.
<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>

26. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019; 366:l4898. doi: 10.1136/bmj.l4898.
27. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
28. Bell SM, Lam DH, Kearney K, Hira RS. Management of Refractory Ventricular Fibrillation (Prehospital and Emergency Department). *Cardiol Clin*. 2018; 36:395-408. doi: 10.1016/j.ccl.2018.03.007.
29. Soar J, Böttiger BW, Carli P, Couper K, Deakin CD, Djärv T, Lott C, Olasveengen T, Paal P, Pellis T, Perkins GD, Sandroni C, Nolan JP. European Resuscitation Council Guidelines 2021: Adult advanced life support. *Resuscitation*. 2021; 161:115-151. doi: 10.1016/j.resuscitation.2021.02.010.
30. Stupca K, Scaturro N, Shomo E, King T, Frank M. Esmolol, vector change, and dose-capped epinephrine for prehospital ventricular fibrillation or pulseless ventricular tachycardia. *Am J Emerg Med*. 2023; 64:46-50. doi: 10.1016/j.ajem.2022.11.019.
31. Deakin CD, Morley P, Soar J, Drennan IR. Double (dual) sequential defibrillation for refractory ventricular fibrillation cardiac arrest: A systematic review. *Resuscitation*. 2020; 155:24-31. doi: 10.1016/j.resuscitation.2020.06.008.
32. Delorenzo A, Nehme Z, Yates J, Bernard S, Smith K. Double sequential external defibrillation for refractory ventricular fibrillation out-of-hospital cardiac arrest: A systematic review and meta-analysis. *Resuscitation*. 2019; 135:124-129. doi: 10.1016/j.resuscitation.2018.10.025.

33. Li Y, He X, Li Z, Li D, Yuan X, Yang J. Double sequential external defibrillation versus standard defibrillation in refractory ventricular fibrillation: A systematic review and meta-analysis. *Front Cardiovasc Med.* 2022;9:1017935. doi: 10.3389/fcvm.2022.1017935.
34. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. *Res Integr Peer Rev.* 2016; 1:2. doi: 10.1186/s41073-016-0007-6.
35. Pilote L, Raparelli V. Participation of Women in Clinical Trials: Not Yet Time to Rest on Our Laurels. *J Am Coll Cardiol.* 2018; 71:1970-1972. doi: 10.1016/j.jacc.2018.02.069.
36. Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. *Circulation.* 2020;141:540-548. doi: 10.1161/CIRCULATIONAHA.119.043594.
37. Malik A, Gewarges M, Pezzutti O, Allan KS, Samman A, Akioyamen LE, Ruiz M, Brijmohan A, Basuita M, Tanaka D, Scales D, Luk A, Lawler PR, Kalra S, Dorian P. Association between sex and survival after non-traumatic out of hospital cardiac arrest: A systematic review and meta-analysis. *Resuscitation.* 2022; 179:172-182. doi: 10.1016/j.resuscitation.2022.06.011.
38. Lakbar I, Ippolito M, Nassiri A, Delamarre L, Tadger P, Leone M, Einav S. Sex and out-of-hospital cardiac arrest survival: a systematic review. *Ann Intensive Care.* 2022; 12:114. doi: 10.1186/s13613-022-01091-9.

Figure Legends

Figure 1. Scheme illustrating pad placement in the different defibrillation strategies.

Figure 2. PRISMA 2020 flow diagram for new systematic reviews, which included searches of databases and registers only.

Figure 3. Forest plot on the mean differences of survival to hospital admission between ADS *vs.* SD from the random-effects meta-analysis.

Table Legend

Table 1. Synopsis of the main features described in papers ($n = 8$) correlating ADS and survival.

Supplementary Figure Legend

Supplementary Figure 1. Funnel plot of the included studies.

Supplementary Figure 2. Forest plot on the mean differences of survival to hospital admission between DSED (2a) / VCD (2b) *vs.* SD from subgroup analysis.


Supplementary Table Legends

Supplementary Table 1. Complete literature search strategy.

Supplementary Table 2. NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.


Supplementary Table 3. Risk of Bias-2 (RoB-2) assessment for randomized trials.

Figure 1. Scheme illustrating pad placement in the different defibrillation strategies.



Notes. DSED: double sequential external defibrillation; VCD: vector-change defibrillation.

Figure 2. PRISMA 2020 flow diagram for new systematic reviews, which included searches of databases and registers only.



* Only human subject-based papers; analysis not in English papers.

Figure 3. Forest plot on the mean differences of survival to hospital admission between ADS vs. SD from the random-effects meta-analysis.





Table 1. Synopsis of the main features described in papers (n = 8) correlating ADS and survival.



Author's name	Year	Duration (months)	Study Design	Patients (n)	Mean age (ys)	Female (n)	Type of ASD	Experimental group (n)	Control group (n)	p	Survival to hospital admission with ADS (%)	Main conclusion
Ross <i>et al</i> (16)	2016	36	Retrospective analysis	279	61.0	73	DSED	50	229	0.830	38.5	DSED in OHCA did not improve neurologically preserved survival
Emmerson <i>et al</i> (17)	2017	18	Retrospective analysis	220	61.9	34	DSED	45	175	N/A	30.0	No clear benefit of DSED vs. SD in rVF
Davis <i>et al</i> (18)	2018	15	Retrospective analysis	25	63.0	3	VCD	16	9	N/A	37.5	VCD in rVF may result in VF termination
Beck <i>et al</i> (19)	2019	48	Retrospective analysis	310	62	75	DSED	71	239	N/A	35.2	DSED was not associated with OHCA outcomes and may be not beneficial in rVF
Mapp <i>et al</i> (20)	2019	36	Case-control study	128	58.4	22	DSED	25	103	0.590	48.0	DSED was not associated with improved survival to hospital admission
Cheskes <i>et al</i> (21)	2020	18	RCT	152	64.0	19	DSED VCD	DSED: 55 VCD: 61	36	N/A	DSED: 32.7 VCD: 24.6	Rates of rVF and ROSC were higher in ADS vs. SD
Kim <i>et al</i> (22)	2020	24	Retrospective analysis	38	62.8	7	DSED	17	21	0.001	82.4	DSED increased survival to hospital admission vs. SD
Cheskes <i>et al</i> (8)	2022	50	RCT	405	63.6	63	DSED VCD	DSED: 125 VCD: 144	136	0.009	DSED: 30.4 VCD: 21.7	Survival occurred more frequently in ADS

Note. ADS: alternative defibrillation strategies; DSED: double sequential external defibrillation; N/A: not available; OHCA: out-of-hospital cardiac arrest; RCT: randomized controlled trial; ROSC: return of spontaneous circulation; rVF: refractory ventricular fibrillation; SD: standard defibrillation; VCD: vector-change defibrillation.

Supplementary Figure 1. Funnel plot of the included studies



Supplementary Figure 2. Forest plot on the mean differences of survival to hospital admission between DSED (2a) / VCD (2b) vs. SD from subgroup analysis.



Supplementary Table 1. Complete literature search strategy.

Search strategy		
“Double-sequential external defibrillation”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”
“Dual-sequential external defibrillation”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”
“DSED”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”
“Vector-change defibrillation”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”
“VCD”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”
“Defibrillation strategies”	AND	“Refractory ventricular fibrillation” “Cardiac arrest” “Ventricular fibrillation” “VF” “Pulseless ventricular tachycardia” “pVT”

Note. DSED: double sequential external defibrillation; pVT: pulseless ventricular tachycardia; VF: ventricular fibrillation; VCD: vector-change defibrillation.

Supplementary Table 2. NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.

Authors	Year	Questions														Quality Rating
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	
Ross <i>et al</i> (16)	2016	Y	Y	Y	Y	Y	Y	Y	N/A	Y	N	Y	N	Y	N	Poor
Emmerson <i>et al</i> (17)	2017	Y	Y	N/A	Y	N	Y	Y	N/A	Y	N	Y	N	Y	N	Poor
Davis <i>et al</i> (18)	2018	N	Y	Y	Y	N	Y	Y	N/A	Y	N	Y	N	N/A	N	Poor
Beck <i>et al</i> (19)	2019	Y	Y	Y	Y	Y	Y	Y	N/A	Y	Y	Y	N	Y	Y	Fair
Mapp <i>et al</i> (20)	2019	Y	Y	Y	Y	Y	Y	Y	N/A	Y	N	Y	N	Y	Y	Fair
Kim <i>et al</i> (22)	2020	Y	Y	Y	Y	Y	Y	Y	N/A	Y	N	Y	N	Y	N	Fair

Note: N/A: Not applicable; Y: Yes; N: No.

Questions

1. Was the research question or objective in this paper clearly stated?
2. Was the study population clearly specified and defined?
3. Was the participation rate of eligible persons at least 50%?
4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?
5. Was a sample size justification, power description, or variance and effect estimates provided?
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?
7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?
8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

10. Was the exposure(s) assessed more than once over time?
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
12. Were the outcome assessors blinded to the exposure status of participants?
13. Was loss to follow-up after baseline 20% or less?
14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

Supplementary Table 3. RoB-2 assessment for randomized trials.

Authors	Experimental Group	Control Group	Outcome	D1	D2	D3	D4	D5	Overall
Cheskes <i>et al</i> (8)	ADS	SD	Survival to hospital admission						
Cheskes <i>et al</i> (21)	ADS	SD	Survival to hospital admission						

Note: ADS: alternative defibrillation strategies; SD: standard defibrillation.

Low risk of bias

Some concerns

High risk of bias

Domains:

D1: Randomization process; D2: Deviations from the intended interventions; D3: Missing outcome data; D4: Measurement of the outcome; D5: Selection of the reported result.